TRIKAFTA

This brand name is authorized in Israel, New Zealand.

Active ingredients

The drug TRIKAFTA contains a combination of these active pharmaceutical ingredients (APIs):

1	Elexacaftor UNII RRN67GMB0V - ELEXACAFTOR
2	Ivacaftor UNII 1Y740ILL1Z - IVACAFTOR
	Ivacaftor is a potentiator of the CFTR protein, i.e., in vitro ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations with reduced channel-open probability compared to normal CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has both low channel-open probability (gating) and reduced channel current amplitude (conductance).
	Read more about Ivacaftor
3	Tezacaftor UNII 8RW88Y506K - TEZACAFTOR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R07AX32	Ivacaftor, tezacaftor and elexacaftor	R Respiratory system → R07 Other respiratory system products → R07A Other respiratory system products → R07AX Other respiratory system products
Discover more medicines within R07AX32

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
IL	מִשְׂרַד הַבְּרִיאוּת	8956
NZ	Medicines and Medical Devices Safety Authority	22462, 22463